The Chinese Hypertrophic Cardiomyopathy Study(CHCS)

Status Recruiting

Clinical Trial Summary

Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac diseases, with a prevalence of ∼0.2%. Sudden cardiac death (SCD), heart failure and stroke are the major poor outcomes of HCM. Although about half of the patients were found to be caused by mutations mainly located in genes encoding sarcomere proteins, the causes in a significant proportion of patients with HCM are still unknown. Even in the patients with sarcomere mutations, the molecular pathways that eventually lead to cardiac hypertrophy are remained to be revealed. Furthermore, HCM presents with significant heterogeneity. SCD risk stratification and prevention by ICD are necessary. However, the strategy of SCD risk stratification recommended by the 2011 ACCF/AHA and 2014 ESC guidelines were based mainly on the evidence derived from American and European countries. The accuracy of these guidelines in Chines patients with HCM was not evaluated yet.

Clinical Trial Description

In the present study, patients with HCM are recruited prospectively after informed consent was given. The investigator will collect the baseline clinical characteristics of the patients at enrollment, including comprehensive physical examination, laboratory testing of blood and urine, electrocardiography, 24-hr Holter, echocardiography, MRI and other examinations if necessary. The specimens retained include blood for all patients and myocardium for patients receive surgery of myocardial myectomy. Multi-omics screening, including genomics, epigenomics, transcriptomics, proteomics, metabolomics, will be performed to identified novel disease genes, signal pathway or processes, genetic risk factors and potential therapy targets of HCM. Furthermore, besides examining the accuracy of SCD risk prediction of the 2011 ACCF/AHA and 2014 ESC guidelines, we will identify novel risk factors associated with the clinical outcomes and construct predictive models suitable for Chinese patients with HCM. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02696135
Study type	Observational
Source	China National Center for Cardiovascular Diseases
Contact	Song Lei, MD.&ph.D
Phone	86-13810532620
Email	clinicalfw@163.com
Status	Recruiting
Phase
Start date	March 23, 2011
Completion date	December 31, 2028

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00253682` - Effects of Highly Active Anti-Retroviral Therapy on Cardiovascular Health in Infants of HIV-Infected Mothers	N/A
Recruiting	`NCT06034405` - Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Terminated	`NCT04222101` - Association of Insulin Resistance and FGF21 on Cardiac Function in Pediatric Dilated Cardiomyopathy	N/A
Recruiting	`NCT05646056` - A Noninterventional, Single-Center Feasibility Study to Evaluate Measures of Heart Failure Risk
Completed	`NCT00692991` - Using Magnetic Resonance Imaging to Evaluate Heart Vessel Function After Angioplasty or Stent Placement Procedures	N/A
Withdrawn	`NCT04905173` - Comparison of Squat-to-Stand Maneuver With Amyl Nitrite, Valsalva, and Exercise Stress Echocardiography in Inducing Latent Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy	N/A
Recruiting	`NCT03251287` - Nitrite in Hypertrophic Cardiomyopathy (HCM) Study	Phase 1
Recruiting	`NCT01165749` - Exercise Study Including Patients With Hypertrophic Cardiomyopathy	N/A
Recruiting	`NCT03057002` - UTSW HP [13-C] Pyruvate Injection in HCM
Recruiting	`NCT03040947` - MRI Sequence and Imaging Protocol Development
Active, not recruiting	`NCT02417311` - Individualized Early Risk Assessment for Heart Diseases
Completed	`NCT03225001` - PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - Nested Registry 3/Valve-in-Valve	N/A
Recruiting	`NCT05524077` - Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia	N/A
Completed	`NCT04164732` - Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy	Phase 2
Recruiting	`NCT06112743` - A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy	Phase 4
Completed	`NCT00001871` - Study of Muscle Abnormalities in Patients With Specific Genetic Mutations	N/A
Completed	`NCT00001459` - Analysis of Heart Muscle Function in Patients With Heart Disease and Normal Volunteers	N/A
Completed	`NCT00005251` - Genetic Analysis of Familial Hypertrophic Cardiomyopathy	N/A
Active, not recruiting	`NCT05556343` - A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy	Phase 2
Completed	`NCT03450252` - Pacemaker Therapy for Drug-refractory Symptoms in Mid-cavity Hypertrophic Cardiomyopathy	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Chinese Hypertrophic Cardiomyopathy Study(CHCS) — CHCS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms